To distinguish FTD from dementia caused by AD, cerebrospinal fluid (CSF) biomarkers demonstrating amyloid and tau pathology and amyloid tracer imaging techniques are widely used in clinical practice (Croisile et al., 2012; Dubois et al., 2014). This evidence concerns the gene MAPT and Alzheimer disease.